Retatrutide (LY3437943) Last Updated: June 2026
Retatrutide Online Store provides this Prescribing Information for educational and reference purposes to support both research and clinical use of Retatrutide.
Product Description
Moreover, retatrutide (LY3437943) is a synthetic triple agonist peptide that targets GLP-1, GIP, and glucagon receptors. In addition to that, It is a next–generation investigational compound designed for the study and potential management of obesity, type 2 diabetes, and metabolic disorders.
Indications and Usage
Retatrutide is being investigated in clinical trials for:
- Chronic weight management in adults with obesity or overweight with comorbidities
- Improvement of glycemic control in adults with type 2 diabetes
- Reduction of liver fat in metabolic dysfunction-associated steatotic liver disease (MASLD)
Note: Retatrutide has not yet received full regulatory approval for general clinical use in all jurisdictions. Hence, Its use should be guided by qualified healthcare professionals.
Dosage and Administration
Research and Clinical Dosing Guidelines:
- Retatrutide is typically administered once weekly via subcutaneous injection.
- Common research protocols involve gradual dose escalation to improve tolerability.
- Starting doses often begin at 0.5 mg – 1 mg, with titration up to 4 mg – 12 mg weekly, depending on study protocols and individual response.
Administration Instructions:
- Inject subcutaneously in the abdomen, thigh, or upper arm.
- Rotate injection sites to minimize discomfort.
- Injectable pens are designed for ease of use; vials require reconstitution with bacteriostatic water (follow proper sterile technique).
Hence, for detailed research protocols, refer to published clinical trial data or institutional guidelines.
Contraindications
- Known hypersensitivity to Retatrutide or any of its components
- Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Severe gastrointestinal disease
- Pregnancy or breastfeeding
Warnings and Precautions
- Thyroid C-Cell Tumors: GLP-1 receptor agonists have been associated with thyroid C-cell tumors in rodent studies.
- Pancreatitis: Monitor for signs of pancreatitis.
- Hypoglycemia: Risk may increase when used with insulin or sulfonylureas.
- Gastrointestinal Effects: Nausea, vomiting, diarrhea, and constipation are common, especially during dose escalation.
- Gallbladder Issues: Monitor for cholelithiasis.
Patients should be under medical supervision, especially during dose titration.
Adverse Reactions
Common adverse events reported in clinical studies include:
- Gastrointestinal disorders (nausea, vomiting, diarrhea, constipation)
- Decreased appetite
- Fatigue
- Injection site reactions
For full safety monitoring, please report any adverse events through our Adverse Event Reporting system.
Storage and Handling
- Store unopened vials and pens in a refrigerator (2°C – 8°C).
- Protect from light and freezing.
- Reconstituted solutions should be used within the recommended period.
- Keep out of reach of children and unauthorized persons.
Clinical Pharmacology
Retatrutide’s triple receptor agonism provides a unique mechanism that may offer enhanced effects on appetite suppression, energy expenditure, and metabolic regulation compared to single or dual agonists.
How Supplied
- 10mg, 15mg, 20mg, 30mg, 50mg lyophilized vials
- Pre-filled injectable pens
Important Legal and Safety Information
Presently, all products from Retatrutide Online Store are supplied for research purposes and clinical use under appropriate medical supervision. Users are responsible for complying with all local laws and regulations.
This Prescribing Information does not replace professional medical advice. Always consult a qualified healthcare provider.
For complete details, please also review our:
Contact Us Email: sales@retatrutideonlinestore.com Phone / Text: +1 (213) 260-3078 (Available 24/7)
